Cannabinoids in Elderly Patients with Dementia

Emerging evidence on cannabinoids for neuropsychiatric symptoms of dementia demands caution, careful dosing, and robust informed consent.

Context and Why It Matters

Clinical practice with cannabinoids requires integrating evolving evidence, endocannabinoid pharmacology, and the operational realities of the clinic. Few therapeutic areas demand more methodological humility.

Evidence and Current Practice

International professional guidelines agree on core principles: rigorous eligibility assessment, gradual titration, active monitoring for adverse effects, and periodic reassessment. The difference between good and poor practice lies in follow-through.

Operational Considerations

Drug-drug interactions deserve specific attention. Both THC and CBD modulate hepatic enzymes and can shift serum concentrations of narrow therapeutic index drugs. Polypharmacy review is mandatory.

Bottom Line

Documenting informed consent in sufficient detail protects both patient and prescriber. Clear records also smooth future care transitions and peer review.